All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Astellas Pharma Inc. and Frequency Therapeutics Inc. have agreed to develop and commercialize Frequency's regenerative therapeutic candidate, FX-322, to treat sensorineural hearing loss (SNHL).
